secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001439222-23-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q4 2022 net income $36.5M on PYRUKYND revenue $4.3M; cash $1.1B
---------------------------------------------------------------------

- PYRUKYND net revenue $4.3M in Q4 2022, $11.7M full year; 78 patients on therapy, up 39% QoQ.
- Net income from continuing ops $36.5M in Q4 vs loss $98.6M in Q4 2021; full-year net loss $231.8M.
- Cash, equivalents and marketable securities $1.1B as of Dec 31, 2022, down from $1.3B year-end 2021.
- Completed enrollment in Phase 2 RISE UP sickle cell study; on track to complete Phase 3 thalassemia enrollment by mid-2023.
- Appointed Tsveta Milanova as chief commercial officer; received EU and Great Britain approvals for PYRUKYND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/0001439222-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/agio-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001439222-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer